Carrolee Barlow has joined E-Scape Bio as chief medical officer. Barlow comes to the San Francisco biotech from the Parkinson’s Institute and Clinical Center, where she was CEO. Her experience also includes executive posts at Amicus Therapeutics (NASDAQ: FOLD) and BrainCells, a company she co-founded to develop treatments for neurological and psychiatric disease.
E-Scape, which raised $63 million in Series A financing in 2017, plans to start clinical trials later this year for its lead program, an experimental treatment for central nervous system-related lysosomal storage disorders. A second program in Parkinson’s disease is expected to start clinical testing in 2020. E-Scape also says it recently acquired research assets from the Parkinson’s Institute for an undisclosed sum.